Skip to main
RXST
RXST logo

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 0%
Hold 67%
Sell 22%
Strong Sell 0%

Bulls say

RxSight Inc is positioned for sustained double-digit growth, supported by an increasing utilization of its light adjustable lens (LDD) technology within a growing installed base. The company demonstrated strong financial performance in 3Q25 by exceeding revenue consensus, while also raising its gross margin guidance for 2025 to 76-77%, indicating healthy operational efficiency. Additionally, RxSight's strategic initiatives to enhance engagement and drive LAL volumes further solidify its potential for positive financial outcomes.

Bears say

RxSight Inc. is facing a challenging outlook as evidenced by a decline in monthly utilization of light adjustable lenses (LALs), which fell from 8.7 in Q2 2025 to 8.0 in Q3 2025 and represents a year-over-year decrease from 10.1 in Q3 2024. Additionally, the company reported a 14% year-over-year decline in revenue to $30.3 million and a significant drop in the placements of light delivery devices (LDDs), down 68% year-over-year and 38% quarter-over-quarter, with only 25 LDDs placed in Q2 2025 against a consensus of 31. The company's risks are compounded by limited adoption of its technology due to the requirement for additional capital equipment, disappointing commercial execution, increased competition in the intraocular lens market, and the potential for future dilutive financing.

RxSight (RXST) has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 9 analysts, RxSight (RXST) has a Hold consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.